Stephen Basil Thomas - 25 Feb 2026 Form 4 Insider Report for Climb Bio, Inc. (CLYM)

Role
Director
Signature
/s/ Chandra Adams, as Attorney-in-Fact
Issuer symbol
CLYM
Transactions as of
25 Feb 2026
Net transactions value
-$350,253
Form type
4
Filing time
27 Feb 2026, 16:05:03 UTC
Previous filing
17 Feb 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Thomas Stephen Basil Director C/O CLIMB BIO, INC., 20 WILLIAM STREET, SUITE 145, WELLESLEY HILLS /s/ Chandra Adams, as Attorney-in-Fact 27 Feb 2026 0002027962

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CLYM Common Stock Sale $235,964 -33,687 -16% $7.00 170,970 25 Feb 2026 Direct F1, F2
transaction CLYM Common Stock Sale $114,289 -16,313 -9.5% $7.01 154,657 26 Feb 2026 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 14, 2025.
F2 The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.0000 to $7.0600, inclusive. The reporting person undertakes to provide the staff of the Securities and Exchange Commission, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) of this Form 4.
F3 The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.0000 to $7.0400, inclusive.